P/E ratio for Agios Pharmaceuticals (AGIO)

P/E ratio history for Agios Pharmaceuticals from 2013 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Xencor XNCR	-11.6	-18.55%	🇺🇸 USA
Exelixis EXEL	126	-981.56%	🇺🇸 USA
Pfizer PFE	13.7	-196.37%	🇺🇸 USA
BioMarin Pharmaceutical BMRN	82.5	-678.93%	🇺🇸 USA
GlaxoSmithKline GSK	9.72	-168.17%	🇬🇧 UK
Eli Lilly LLY	138	-1,067.62%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.